SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-199226
Filing Date
2022-07-21
Accepted
2022-07-21 16:46:10
Documents
19
Period of Report
2022-07-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d356171d8k.htm   iXBRL 8-K 32793
2 EX-1.1 d356171dex11.htm EX-1.1 204983
3 EX-5.1 d356171dex51.htm EX-5.1 9300
4 EX-99.1 d356171dex991.htm EX-99.1 8525
8 GRAPHIC g356171g0721091027192.jpg GRAPHIC 1649
9 GRAPHIC g356171g0721091731392.jpg GRAPHIC 6662
10 GRAPHIC g356171g0721093441435.jpg GRAPHIC 2993
11 GRAPHIC g356171g0721093441623.jpg GRAPHIC 3026
  Complete submission text file 0001193125-22-199226.txt   468761

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA verv-20220720.xsd EX-101.SCH 2858
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220720_lab.xml EX-101.LAB 18739
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220720_pre.xml EX-101.PRE 11709
13 EXTRACTED XBRL INSTANCE DOCUMENT d356171d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 221097554
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences